"A new report provides details on 45 individuals from 13 countries who developed a chronic ailment soon after receiving the human papillomavirus (HPV) vaccine.
After a mean period of 4 years after HPV vaccination, 43 of these individua"...
A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
Menomune - A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W- 135 Combined, is a vaccine for subcutaneous injection. Menomune - A/C/Y/W-135 vaccine consists of a sterile lyophilized preparation of the group-specific polysaccharide antigens from N meningitidis, Group A, Group C, Group Y, and Group W-135. Nmeningitidis are cultivated on Mueller Hinton casein agar7 and grown in Watson Scherp casamino acid media8. The purified polysaccharide is extracted from the N meningitidis cells and separated from the media by procedures which include centrifugation, detergent precipitation, alcohol precipitation, solvent or organic extraction, and diafiltration. No preservative is added during manufacture.
The diluent (0.6 mL) for the single dose presentation contains sterile, pyrogen-free distilled water without preservative. The diluent (6 mL) for the multidose presentation contains sterile, pyrogen-free distilled water and thimerosal, a mercury derivative, which is added as a preservative for the reconstituted vaccine. [See HOW SUPPLIED/Storage and Handling]
After reconstitution with diluent, the vaccine is a clear colorless liquid solution. Each 0.5 mL dose contains 50 mcg of polysaccharide from each of serogroups A, C, Y, and W-135. Reconstituted vaccine from a multidose vial also contains 25 mcg mercury per dose.
Each dose of vaccine contains 2.5 mg to 5 mg of lactose added as a stabilizer.9
Potency is evaluated by measuring the molecular size of each polysaccharide component using a column chromatography method as standardized by the US Food and Drug Administration (FDA) and the World Health Organization (WHO)10 for Meningococcal Polysaccharide Vaccine.
7 Mueller H, et al. A protein-free medium for primary isolation of the gonococcus and meningococcus. Proc Soc Exp Biol Med 1941;48:330.
8 Watson RG, et al. The specific hapten of group C (group II a) meningococcus. II. Chemical nature. J Immunol. 1958;81:337.
10 WHO Technical Report Series, 1981;No.658.
What are the possible side effects of this vaccine (Menomune A/C/Y/W-135)?
Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another meningococcal vaccine in the future, you will need to tell the doctor if the first shot caused any side effects.
Developing meningitis (infection of the spinal cord and lining of the brain) is much more dangerous to your health than receiving this vaccine. However, like any medicine, this vaccine can cause side effects but the risk of serious side effects is extremely low.
Get emergency medical help if you have any of these signs of an allergic...
What are the precautions when taking meningococcal polysaccharide vaccine (Menomune)?
See also How to Use and Drug Interactions sections.
Before you receive this vaccine, tell the health care professional if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as latex or dry natural rubber that can be found in the vial stopper), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before receiving this vaccine, tell your health care professional your medical history, especially of: your vaccination/immunization history, recent illness or fever, immune system problems (e.g., due to cancer treatment, organ transplant, HIV).
Some brands of this product may contain a small amount of mercury from a preservative (thimerosal). Consult your doctor for more...
Last reviewed on RxList: 9/18/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Menomune Information
Report Problems to the Food and Drug Administration
Find out what women really need.